Truist Securities Downgrades Marinus Pharmaceuticals (MRNS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Marinus Pharmaceuticals (MRNS) PT Lowered to $0.50 at Baird
October 24, 2024 1:59 PM EDTBaird analyst Brian Skorney lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $0.50 (from $2.00) while maintaining a Neutral rating.
The analyst comments "Negative on clinical and strategic update. The company announced this morning that Phase 3 study of ganaxolone in... More



